Progranulin Deficiency Improves Metabolic Stress Yet Falls Short of Sodium-Glucose Cotransporter-2 Inhibition in Autophagy-Linked Renal Protection

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have reshaped the clinical landscape of diabetic kidney disease (DKD), delivering kidney protection that extends beyond glycemic effects across multiple outcome trials [1][2][3][4].However, DKD progression is heterogeneous, and substantial residual risk persists, particularly in patients with prominent tubulointerstitial injury, lipid dysmetabolism, and impaired cellular quality-control pathways such as autophagy [5,6].This residual risk has sharpened interest in metabolic and inflammatory mediators that link adipose tissue, liver, and kidney phenotypes.In this context, progranulin (PGRN) has emerged as an intriguing candidate.PGRN has been described as an adipokine implicated in high-fat diet-induced insulin resistance and adipose inflammation, with mechanistic links to cytokine signaling and metabolic dysfunction [7].At the same time, PGRN is increasingly recognized for its roles in lysosomal biology, raising the possibility that altering PGRN signaling could produce tissue-specific trade-offs that are metabolically favorable in one organ but potentially detrimental in another [8,9].Sakuma et al. [10] address this complexity directly by comparing PGRN knockout (KO) with pharmacologic SGLT2 inhibition using tofogliflozin in a murine model of diabetes.Their study provides a direct, like-for-like comparison of two interventions that both improve metabolic stress yet diverge at the level of kidney microstructure and autophagy signaling.In wild-